Spectrum Pharmaceuticals
11500 S. Eastern Ave
Henderson
NV
89052
United States
Tel: 1-702-835-6310
Website: https://www.sppirx.com/
81 articles about Spectrum Pharmaceuticals
-
Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction
7/31/2023
Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology.
-
Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals
7/27/2023
Assertio Holdings, Inc. announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which Assertio will acquire Spectrum in an all-stock and contingent value rights transaction.
-
Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
5/17/2023
Spectrum Pharmaceuticals, Inc. announced today that on May 16, 2023, the Company received a written notification from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
-
Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update
5/9/2023
Spectrum Pharmaceuticals, Inc. announced today financial results for the three-month period ended March 31, 2023, and provided a corporate update.
-
Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction
4/25/2023
Assertio Holdings, Inc. and Spectrum Pharmaceuticals, Inc. announced that they have entered into a definitive agreement pursuant to which Assertio will acquire all outstanding shares of Spectrum in an all-stock and contingent value rights transaction.
-
Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
3/17/2023
Spectrum Pharmaceuticals, Inc. today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a corporate update on Wednesday, March 22, 2023, at 8:30 a.m. Eastern/5:30 a.m. Pacific.
-
Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services
2/8/2023
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2023.
-
Spectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results
1/31/2023
Spectrum Pharmaceuticals, Inc. today announced business highlights and preliminary ROLVEDON net sales for the quarter and year ended December 31, 2022.
-
Spectrum Pharmaceuticals Announces New Employment Inducement Grant for Commercial Staff
1/26/2023
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on January 26, 2023, Spectrum’s Board of Directors granted an aggregate of 20,833 inducement restricted stock units (“RSUs”) to a commercial non-executive employees.
-
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff - December 27, 2022
12/27/2022
Spectrum Pharmaceuticals announced that on December 27, 2022, Spectrum’s Board of Directors granted an aggregate of 206,059 inducement restricted stock units to commercial non-executive employees who were hired specifically for the launch of ROLVEDON.
-
Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors
12/6/2022
Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors.
-
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff - December 05, 2022
12/5/2022
Spectrum Pharmaceuticals announced that on December 5, 2022, Spectrum’s Board of Directors granted an aggregate of 736,988 inducement restricted stock units to commercial non-executive employees who were hired specifically for the launch of ROLVEDON.
-
Spectrum Pharmaceuticals made the call Friday to slash three-fourths of its workforce on the heels of a Complete Response Letter from the FDA.
-
Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection
11/25/2022
Spectrum Pharmaceuticals, Inc. today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Spectrum’s New Drug Application (NDA) for poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring HER2 exon 20 insertion mutations.
-
The FDA has a number of PDUFA dates for the remainder of November for Spectrum, ImmunoGen, Scynexis and Y-mAbs.
-
Spectrum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/10/2022
Spectrum Pharmaceuticals, Inc. announced today financial results for the three-month period ended September 30, 2022.
-
Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™ (eflapegrastim-xnst) Injection
10/21/2022
Spectrum Pharmaceuticals, Inc. today announced the commercial availability of ROLVEDON™ (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
-
Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing
9/23/2022
Spectrum Pharmaceuticals, Inc. today announced that it has entered into a five-year debt financing agreement with investment affiliates managed by SLR Capital Partners, LLC (SLR) for a term loan facility of up to $65 million.
-
The U.S. FDA had a busy week with a range of drug approvals, advisory committee meetings and classification announcements.
-
Shares of Spectrum Pharmaceuticals plunged 33% upon the release of briefing documents for an FDA advisory meeting regarding poziotinib